Orion Pharma (DHA:ORIONPHARM) YoY EPS Growth: -3,350.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
75 GF Score
Price BDT25.00
GF Value BDT19.56
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma YoY EPS Growth?

Orion Pharma DHA:ORIONPHARM +0.76% 75 YoY EPS Growth is -3,350.00% as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 75/100 and a GF Value™ of BDT19.56 (Modestly Overvalued). The stock has 8 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Orion Pharma's YoY EPS Growth for the quarter that ended in Mar. 2026 was -3,350.00%.

Orion Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was BDT-0.65.

Orion Pharma YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Orion Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma YoY EPS Growth Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.20 -9.73 -24.31 -50.36 -230.15

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -95.24 -449.14 -225.00 -27.27 -3,350.00
DHA:ORIONPHARM
75GF Score
Orion Pharma Ltd DHA:ORIONPHARM
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Orion Pharma's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-1.77-1.36)/ | 1.36 |
=-230.15 %

Orion Pharma's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.65-0.02)/ | 0.02 |
=-3,350.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -3,350.00% mean?
Orion Pharma (DHA:ORIONPHARM) has a YoY EPS Growth of -3,350.00% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Orion Pharma and its competitors.
Is Orion Pharma's YoY EPS Growth too high?
Orion Pharma's current YoY EPS Growth is -3,350.00%. Overall, Orion Pharma has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's YoY EPS Growth compare to CEG and VST?
Orion Pharma's YoY EPS Growth of -3,350.00% can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for an Utilities - Independent Power Producers company?
A good YoY EPS Growth depends on the Utilities - Independent Power Producers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Orion Pharma and its competitors. Orion Pharma's current YoY EPS Growth is -3,350.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.56, compared to a current price of BDT25.00 — trading 27.8% above its estimated fair value. The current YoY EPS Growth is -3,350.00%. Orion Pharma's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current YoY EPS Growth is -3,350.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT25.00 is trading 27.8% above its estimated GF Value™ of BDT19.56. GuruFocus considers Orion Pharma to be Modestly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • YoY EPS Growth: -3,350.00%
  • GF Value™: BDT19.56 vs. price of BDT25.00 (27.8% above fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
75GF Score

Get the complete analysis for DHA:ORIONPHARM

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT25.00
Price
BDT19.56
GF Value